Time spent on Dabrafenib+Trametinib 

Interesting spider graph at ECC2015 on Dabrafenib and Trametinib a known combination of a Braf inhibitor and a Mek inhibitor. A subset of patients can make it longer than others -meaning that their tumour resistance to the treatment is occurring much later (>2 years). As seen patients with a slow reduction of tumours tend to stay longer on treatment than the ones experiencing a rapid shrinkage.

ORR* to

immunotherapy in patients subgroups CheckMate 067

Patients with  PDL1>5% respond well to

both combination Ipi +Nivo or Nivo alone.

Patients wild type respond better to combination Nivo+ IPI than to Nivo alone.


Finally patients with lower LDH have respond the best to both treatments (combi or mono).

Efficacy of treatments for the total number of patients is known from ASCO2015 -median PFS is 11.5 months for NIVO + IPI versus 6.9 months for NIVO alone and 2.9 months for IPI alone.
* - overall response rate

Educative at #ECC2015: Treatments landscape in melanoma 

Treatment options for both Braf positive and Braf wild melanoma.
Obviously there are more choices and opportunities to alternate the treatments for Braf positive patients.
Chemotherapy is the last option. Strict monitoring at 6-8 months looks essential to early catch the disease progression.
https://www.europeancancercongress.org/Scientific-Programme/Abstract-search#
Abstract 3303.